**Evidence Table H-1b. Support observational studies**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author, yearCountryOverallQuality Rating** | **Population: Eligibility Criteria** | **Population: Exclusion Criteria** | **Population Data: Number Screened/ Eligible/ Enrolled/ Analyzed** | **Age****Sex****Race** | **Intervention: Type** | **Intervention Ulcer Type/Severity at Baseline (Intervention Onset)** |
| Ochs, 200524USFair | Enrolled in National Pressure Ulcer Long-Term Care Study (NPULS) 18 years old or older Length of stay of 14 days or longerOne or more documented PUs in medical record;Treated with one of the three groups of support surfaces | Treated on support surface for less than 5 days | 2,486/664/664/664  | Age (Mean): 78 Female: 63% Race (available for 28% of sample):Caucasian: 66.5%African American: 28.6%Other: 4.9% | Support Surface | Stage:Treatment A:Not Staged: 2% (10)Stage I:10% (47)Stage II: 62% (288)Stage III: 13% (59)Stage IV: 7% (32)Eschar: 6% (27)Treatment B:Not Staged: 3% (3)Stage I: 8% (9)Stage II: 38% (45)Stage III:19% (23)Stage IV: 24% (29)Eschar: 8% (10)Treatment C:Not Staged: 0Stage I: 4% (3)Stage II: 18% (15)Stage III: 17% (14)Stage IV: 54% (44)Eschar: 7% (6) |
| Valente, 201225USPoor | All patients admitted to a geriatric center between 7/1/2001 and 6/30/2002A Brandon score of 16 or higher (high risk)Existing PU requiring institution of pressure reduction product | Length of stay less than 10 daysDevelopment of a stage III or IV PU and moved to a low-air loss bed | NR/122/122/122 | Age (Mean): 68 yearsFemale: 65% Race: Caucasian 77% African American 23% | Support: Improved Gel and AP | Stage I and II only |
| Warner, 199226USPoor | 21 years or olderPresence of a PU less than 12 cm in diameterUse of LAL or Foam mattress | Lesions due to peripheral vascular diseaseMultiple system failureSepticemiaPlanned graft or flap surgery of PURestrictive immobility | NR/NR/20/20 | Age (Mean): 64 yearsFemale: 45% Race:White 80% Black: 10% Hispanic 10% | Support: LAL beds | Treatment A: Stage 1: 6% (1) Stage II: 29% (5)Stage III: 41% (7)Stage IV: 0Eschar/Slough: 24% (4)Treatment B:Stage 1: 7% (1) Stage II: 29% (4)Stage III: 19% (4)Stage IV: 0Eschar/Slough: 35% (5) |

| **Evidence Table H-1b: Support Observational Studies, continued** |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, yearCountryOverall Quality Rating** |  **Treatment A** | **Treatment B** | **Treatment C** | **Outcomes: Complete Wound Healing** | **Outcomes: Wound Surface Area** | **Outcomes: Healing Time** | **Outcomes: Pain** | **Outcomes: Infection Rate** | **Outcomes: Osteomyelitis** |
| Ochs, 200524USFair | Static overlays and replacement mattresses Air fluidized beds | Static overlays and replacement mattresses | LAL beds, powered, and non-powered overlays and mattresses. | NR | Mean change in cm2/per weekAll ulcersTreatment A: 5.2 Treatment B: 1.5 Treatment C: 1.8 p=0.0071 Stage I/II:Treatment A: 8.8 Treatment B: 1.6 Treatment C: 2.4p=0.0229Stage III/IV/eschar:Treatment A: 4.1Treatment B: 1.1Treatment C: 1.4ANOVA p=0.0259Group 3 statistically significantly betterSubset stage III/IV with baseline size 20-75 cm2 Group 1: 2.5 Group 2: -2.1 (Group 3: 2.3 Groups 1 and 3 significantly better than 2 (p=0.0399) | NR | NR | NR | NR |
| Valente, 201225USPoor |  AP overlay | Gel Overlay | NA | Complete Wound Healing for PUs Present on AdmissionTreatment A: 27% (13/48)Treatment B: 17% (5/30)Complete Wound Healing PU Developed During StayTreatment A: 22% (15/67)Treatment B: 11% (6/55)Not significantly differentp<0.05 | Treatment A: 31.3 cm2 per weekTreatment B: 31.9 cm2 per weekp=NS | NR | NR | NR | NR |
| Warner, 199226USPoor | LAL Bed | Foam Mattress with loose-fitting cover | NA | NR | Mean Progress Toward Wound Closure:Treatment A: 0.16 cm Treatment B: 0.27 cm p>0.05 | NR | NR | NR | NR |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Evidence Table H-1b: Support Observational Studies, continued** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Author, yearCountryOverall Quality Rating** | **Outcomes: Recurrence Rate** | **Other Outcomes: Specify** | **Timing: Duration of Followup** | **Setting** | **Setting Comment** | **Harms: Pain** | **Harms: Dermatologic Complication** | **Harms: Bleeding** | **Harms: Infection** | **Severe Adverse Events** | **Withdrawal Due to Adverse Events** | **Overall Adverse Events Rate** | **Funding Source** |
| Ochs, 200524USFair | Hospitalizations and ER visitsNumber (%) of patients with 1 or moreTreatment A: 7% (47) Treatment B: 10% (23) Treatment C: 19% ( 6)Probability of differenceB vs. C p=0.0080A vs. C p=0.0195A vs. B p=0.4184 | NR | 3 months  | Hospital - Nursing home/Long-term care | NR | NR | NR | NR | NR | NR | NR | Analyses were done on person level and episode level, where episode is each ulcer for a 7-10 day period. As conclusion are the same, person level is included here. | Hill-Rom |
| Valente, 201225USPoor | NR | NR | Mean Length of StayTreatment A: 133 days Treatment B: 83 days  | Chronic Care Beds/Long-term care | NR | NR | NR | NR | NR | NR | NR | NR | John A. Hartford Foundation/ American Federation for Aging and Research |
| Warner, 199226USPoor | NR | NR | 4 weeks | Hospital | NR | NR | NR | NR | NR | NR | NR | NR | Sigma Theta Tau International |